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Abstract 
It has recently been reported that bisphosphonates are the most common treatment for osteoporotic patients. How-
ever, they are many problems, including poor bioavailability and adherence, as well as adverse drug reactions. There-
fore, intravenous administration of bisphosphonates has been developed to resolve these problems. In Japan today, 
alendronate and ibandronate have been approved for intravenous administration, and they have advantages, such as 
good adherence and better gastrointestinal tolerability, compared to oral administration. We attempted to confirm 
the effects of administration of intravenous alendronate, which is not inferior to oral administration, for osteoporotic 
patients in earlier research. 200 consecutive Japanese over 70 years-old postmenopausal women who visited the first 
author’s orthopedic clinic and had femoral neck or lumbar spine bone mineral density (BMD) values more than 2.5 SD 
lower than the reference values were randomly enrolled in this study. 100 subjects were recruited for administration 
of intravenous alendronates because of their poor adherence, no respond of treatment status, and gastrointestinal 
adverse effects. Furthermore, 10 of these subjects were excluded due to discontinuation, and a total of 90 subjects 
were eligible for the intravenous group. The remaining 50 patients received oral alendronate. The present study also 
showed no significant difference between intravenous and oral administration with respect to BMD, biochemical 
bone turnover markers, and the incidence of fractures. These results show that intravenous administration of alen-
dronate is not inferior to oral alendronate for the treatment of osteoporosis. Therefore, intravenous administration of 
alendronate can be recommended if patients do not tolerate or adhere to oral bisphosphonates.
© 2015 Horikawa et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Although it has been widely recognized that alendronate 
(ALN) is the drug of first choice for the treatment of oste-
oporosis, its adverse effects with oral intake are an issue. 
To address these problems, intravenous bisphosphonate 
regimens have been developed. In Japan today, alen-
dronate and ibandronate have been approved for intrave-
nous administration for the treatment of osteoporosis. A 
randomized, double-masked, comparative study was ini-
tiated to examine the safety of intravenous administration 
of alendronate in a clinical trial in Japanese patients with 
osteoporosis (Shiraki et al. 2012). However, few compara-
tive studies to confirm the effectiveness of intravenous 
administration of alendronate have been conducted in 
patients with osteoporosis. Therefore, the primary objec-
tive of the present study was to confirm that intrave-
nous administration of alendronate is not inferior to oral 




This study was designed as a 52-week, prospective, non-
randomized study involving parallel-group comparison 
between intravenous ALN 900  µg (alendronate sodium 
hydrate, Teijin Pharmaceutical Company, Tokyo, Japan) 
once monthly and oral ALN 35 mg (alendronate sodium 
hydrate, Teijin Pharmaceutical Company) once weekly. 
Both of these are almost same dosage (Huruhata et  al. 
2013).
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Patients with poor adherence to oral administra-
tion and/or gastrointestinal problems were assigned 
to receive intravenous drip infusion of ALN (intrave-
nous drip group), while the others were assigned to oral 
ALN administration (oral group). All patients gave their 
informed consent prior to the study. This study was per-
formed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki and its amendments.
Participants
A total of 200 consecutive Japanese over 70  years-old 
postmenopausal women who visited the first author’s 
orthopedic clinic between March 2013 and April 2014 
and had femoral neck or lumbar spine bone mineral 
density (BMD) values more than 2.5 SD lower than the 
reference values were randomly enrolled in this study. 
Of these, those who preferred other medical care and 
refused to provide their informed consent were excluded 
from this trial. The remaining 150 eligible patients were 
recruited. Of these, 100 subjects were recruited for 
administration of intravenous alendronates because of 
their poor adherence, no respond of treatment status, 
and gastrointestinal adverse effects. Those who com-
plained of gastrointestinal (GI) problems want to try to 
other administration therapy which was similar alen-
dronate. Furthermore, 10 of these subjects were excluded 
due to discontinuation, and a total of 90 subjects were 
eligible for the intravenous group. The remaining 50 
patients received oral alendronate (Fig. 1).
BMD measurements
Areal BMD measurements were performed at the proxi-
mal femur and lumbar spine using dual energy X-ray 
absorptiometry (DXA, Hologic QDR Discovery W type; 
Toyo Medic., Tokyo, Japan), and some of the patients 
who could not visit our clinic were examined by forearm 
BMD (DTX200; Datex DSM, Courtaboeuf Cedex, France, 
Japan) at a related facility.
Fracture incidence rates and adverse events
Incidence rates of fractures, including vertebral and non-
vertebral fractures, and adverse drug reactions (bone and 
muscle pain, pyrexia, myalgia, fatigue, lymphopenia, etc.) 
were calculated.
Body mass index
Body mass index (BMI) was measured in all subjects who 
participated in this study.
Bone turnover markers
Serum bone specific alkaline phosphatase (BAP) and 
serum collagen type 1 cross-linked N telopeptide (NTX) 
were measured at baseline, 6 months, and 12 months.
Statistical analysis
Statistical analysis was performed using Microsoft Office 
Excel and the Statcel 3 program (OMS, Inc., Hyogo, 
Japan). Both BMD and bone turnover markers for each 
subject were analyzed by Student’s t test to compare dif-
ferences between the two groups. For the incidences of 
fractures and adverse drug reactions, the Chi square test 
was used to evaluate the significance of differences. All 
results of statistical tests were regarded as significant 
with p < 0.05.
Results
Data from the intravenous drip group and the oral pre-
scription group are shown in Table  1. There were no 
significant differences in age, BMI, and the incidences 
of fractures and adverse drug reactions between these 
groups. Both of two new fractures were all vertebral frac-
ture in intravenous drip group, of those which one was 
L1 and other was Th8. All of these patients visited twice 
a month after injury through 6 months. Decompression 
and deformity have not progressed during this period. 
Two adverse drug reactions were found in oral prescrip-
tion group, all of those were pyrexia and they recovered 
soon. According to the DXA analysis, there was no dif-
ference in the change of BMD between these groups in 
the lumbar spine (oral group: 0.585, 0.595, 0.605, intra-
venous group: 0.552, 0.553, 0.568, sequentially) femur 
(oral group: 0.464, 0.467, 0.478, intravenous group: 0.491, 
0.482, 0.506, sequentially) and forearm (oral group: 0.231, 
0.232, 0.234, intravenous group: 0.256, 0.261, 0.269, 
sequentially), (Fig.  2a–c, g/cm2). There was also no sig-
nificant difference in bone turnover markers between the 
intravenous group (BAP: 23.2, 16.3, 23.0, NTX: 20.7, 14.9, 
21.3, sequentially) and the oral group (BAP: 21.5, 21.8, 
21.6, NTx: 19.8, 20.1, 20.0, sequentially), (Fig. 3a, b, BAP: 
U/l, NTX: nmol BCE/l).
Discussion
There have been only a few reports that compared the 
efficacy and safety of alendronate given intravenously 
once a month and orally once a week in Japanese patients 
with osteoporosis (Shiraki et  al. 2012; Miyakoshi 2014). 
Therefore, the present study was performed to attempt 
to confirm the efficacy and safety of intravenous alen-
dronate, which previous research has suggested is 
non-inferior to oral alendronate (Shiraki et  al. 2012). 
Although this study was a limited developmental study 
with a short-duration (1 year) and a relatively small num-
ber of patients, we did not find any significant differences 
between these groups with regard to age, BMI, incidence 
ratio of previous fractures. So we confirm that there are 
no dysbalance about them. This study results also showed 
no inferiority of intravenous administration compared 
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to oral administration in the changes in percentages of 
BMD from the baseline in the lumbar spine, femur, and 
forearm. Furthermore, the bone turnover markers (BAP 
and NTX) were changed to a similar level by the two 
treatments, and with respect to the safety of alendronate, 
no clinically significant differences in the incidences of 
fractures and adverse drug reactions were seen.
In addition, intravenous group seems to be low healthy 
because of GI problem, we could not find any other 
health problems without it. To take this condition into 
Patients enrolled: n=200
Patients excluded because 
of,hope for other medical care: 
n=40
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prevention of  
fracture(n=10)
discontinued (n=10)
No effect of 
increasing of BMD 
(n=20)
Fig. 1 The participant selection process. Data on age, height, weight, BMI, and incidences of fracture and adverse drug reactions were collected 
from all participants
Table 1 Comparisons of baseline variables in intravenous drip and oral prescription group
a Student’s t test
b χ2 test
Oral prescription group (n = 50) Intravenous drip group (n = 90) p value
Age (years) 76 ± 7.9 80 ± 6.4 0.200a
Height (cm) 153 ± 4.2 150 ± 5.3 0.015a
Weight (kg) 54.8 ± 8.9 50.2 ± 7.6 0.023a
BMI (kg/m2) 25 ± 4.0 24.1 ± 3.6 0.201a
BMD: femur (g/cm2) 0.464 ± 0.035 0.491 ± 0.052 0.538a
BMD: lumbar spine (g/cm2) 0.585 ± 0.042 0.552 ± 0.028 0.052a
Previous fracture (n) 5 10 0.158b
Incidence ratio of fracture (n) 0 2 0.205b
Adverse drug reactions (n) 2 0 0.204b
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consideration, we regarded this group as having the same 
healthy condition.
Treatment of osteoporosis by intravenous infusion of 
bisphosphonates results in better bioavailability than 
by oral bisphosphonates, which was estimated at about 
0.7  % (Gertz et  al. 1995). The present data confirmed 
that the change in BMD was not significantly different 
between the two. These data may suggest that bioavail-
ability is not important whether the patients are carefully 
instructed to follow the dosing guidance for oral medica-
tion or given intravenous administration.
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Fig. 2 Statistical analysis of changes in bone mineral density 
between the oral group and the intravenous drip group (Student’s t 
test). These patients had no compliance about all kinds of BMD which 
were lumbar spine, femoral neck and forearm. Of these BMD, they 
choose only one examination area due to time and cost. Moreover, 
they had a few chance to measure their BMD due to lack of visit. a 
Lumbar spine, b femur, c forearm
−
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Fig. 3 Comparison of changes in biochemical bone turnover mark-
ers between the oral group and the intravenous group (Student’s 
t test). I suppose bone turnover suppression were relatively low 
because of effect of other drug combination such as eldecalcitol 
or past oral alendronate prescription. a Bone alkaline phosphatase 
(BAP), b collagen type 1 cross-linked N telopeptide (NTX)
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On the other hand, intravenous infusion of bisphos-
phonates is known to induce a transient acute phase reac-
tion with bone and muscle pain, pyrexia, myalgia, fatigue, 
lymphopenia, etc., and in some patients one might hesi-
tate to prescribe oral alendronate because of issues with 
gastrointestinal tolerability, such as when there is kypho-
sis of the lumbar spine, which may be associated with 
gastroesophageal reflux disease (Miyakoshi et  al. 2009). 
However, the above-mentioned adverse drug reactions 
did not occur in the present study.
Considering these facts and the lack of a significant 
difference in the incidence of fractures, the present 
study confirmed the efficacy and safety of intravenous 
alendronate 900  μg once a month, which were similar 
to those of weekly oral alendronate in Japanese patients 
with osteoporosis. Intravenous alendronate is considered 
to be useful instead of oral alendronate to achieve the 
expected effect of prevention of fractures if the patients 
have poor adherence for oral prescriptions (Brookhart 
et al. 2007; Siris et al. 2006).
Conclusion
As previously reported, intravenous administration of 
alendronate is not inferior to oral alendronate for the 
treatment of osteoporosis. No significant differences 
were seen between the intravenous and oral alendronate 
groups with respect to changes in BMD, bone turnover 
markers, prevention of vertebral fractures, and adverse 
events. We need further investigation in long-term 
period and more number of patients in this study.
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